Jamal Rana: Coronary Artery Calcium Is an Evidence-Based Diagnostic Test for CAD
Jamal Rana, Professor in the Department of Clinical Science at Kaiser Permanente Bernard J. Tyson School of Medicine, shared on LinkedIn:
”Our crucial viewpoint paper on Coronary Artery Calcium as a diagnostic test, out in JACC Journals Imaging. Heart disease remains 1 killer. Time to be proactive and prevent.
- CAC imaging is an evidence-based test for diagnosing and managing CAD. Per current guidelines, in patients where ASCVD risk factor screening indicates borderline or intermediate risk, using CAC for diagnosing and staging CAD is recommended.
- Most individuals shown to lack evidence of CAD (ie, CAC =0) can safely defer medical therapy while those diagnosed with CAD can have their medical therapy tailored to their extent of the disease.
- The time is overdue for this coverage to be widely implemented so that all patients at borderline or intermediate risk, not just those who can pay out of pocket, have access to CAC imaging for guideline-based cardiovascular care.
- Expanding coverage for Medicare-age patients is particularly urgent given that seniors are proportionately affected by ASCVD yet excluded from most state-level mandates. Equal access across both Medicare and commercial payers is necessary to close this gap.”
Title: Coronary Artery Calcium (CAC) Imaging as a Diagnostic Test
Authors: Morteza Naghavi, Nathan D. Wong, Michael V. McConnell, David J. Maron, Khurram Nasir, Claudia I. Henschke, David F. Yankelevitz, Zahi A. Fayad, Rozemarijn Vliegenthart, Kim A. Williams, Sr., Roxana Mehran, Mathew Budoff, Daniel Berman, Jamal S. Rana, Prediman K. Shah, Robert A. Kloner, Jagat Narula, Philip Greenland, Valentin Fuster
Read the full article here.
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 17, 2025, 15:24Laura Dormer on a Motor Relearning Program for Chronic Stroke Patients
-
Dec 17, 2025, 15:01WSO: United Nations Has Formally Adopted the Political Declaration on NCDs and Mental Health
-
Dec 17, 2025, 14:44Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
-
Dec 17, 2025, 14:29Sarah Richardson: Feeling So Proud to Be a Part of the Advocacy Team for the HFA
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID